跳至主要内容
临床试验/NCT01779258
NCT01779258已完成3 期

Emollients in the Management of Atopic Dermatitis in Children: Prevention of Flares.

Pierre Fabre Medicament0 个研究点目标入组 347 人开始时间: 2013年2月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
3 期
状态
已完成
入组人数
347
主要终点
Percentage of patients with at least one flare over the treatment period

研究概览

简要总结

The purpose of this study is to confirm that emollients play a major role in the maintenance therapy after clearing of inflammatory lesions and can reduce occurrence of flares in children with atopic dermatitis.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
None

入排标准

年龄范围
2 Years 至 6 Years(Child)
性别
All
接受健康志愿者

入选标准

  • Age between 2 and 6 years included,
  • Presenting with atopic dermatitis, with at least one duly documented flare treated by corticosteroids within the previous 6 months, and presenting a current flare (objective Scoring for Atopic Dermatitis (SCORAD score) is [15-40] at inclusion),
  • After treatment of the current flare, patients should have for randomization an Objective SCORAD score < 15, with Xerosis intensity≥ 1 and no subjective signs

排除标准

  • Severe form of atopic dermatitis requiring either systemic corticosteroid treatment and/or antibiotic or antiviral treatment and/or hospitalisation,
  • Primary bacterial, viral, fungal or parasitic skin infection,
  • Ulcerated lesions, acne or rosacea,
  • Dermatological disease other than atopic dermatitis which could interfere with the assessment,
  • Immunosuppression,

研究组 & 干预措施

Group 1

Experimental

glycerol, paraffin (liquid and white soft), Locatop@

, Locapred@

干预措施: Locapred@ (Drug)

Group 2

Other

Active control arm, Locatop@, Locapred@

干预措施: Atopiclair® (Device)

Group 2

Other

Active control arm, Locatop@, Locapred@

干预措施: Locatop@ (Drug)

Group 1

Experimental

glycerol, paraffin (liquid and white soft), Locatop@

, Locapred@

干预措施: Locatop@ (Drug)

Group 2

Other

Active control arm, Locatop@, Locapred@

干预措施: Locapred@ (Drug)

Group 3

Other

Absence of emollient treatment, Locatop@, Locapred@

干预措施: Locatop@ (Drug)

Group 3

Other

Absence of emollient treatment, Locatop@, Locapred@

干预措施: Locapred@ (Drug)

Group 1

Experimental

glycerol, paraffin (liquid and white soft), Locatop@

, Locapred@

干预措施: glycerol, paraffin (liquid and white soft) (Drug)

结局指标

主要结局

Percentage of patients with at least one flare over the treatment period

时间窗: 12 weeks of treatment.

A flare is defined as following: measurable increased extend or intensity of lesions in less than 2 weeks under continued treatment corresponding to a significant increase in medical score (\> 25%) or to the introduction of a new line of therapy(topical corticosteroid).

次要结局

未报告次要终点

研究者

申办方类型
Industry
责任方
Sponsor

相似试验